Overview

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).

Phase:

Phase 3

Details

Lead Sponsor:

Vifor Inc.
Vifor Pharma

Collaborators:

American Regent, Inc.
ICON Clinical Research
Luitpold Pharmaceuticals

Treatments:

Ferric Compounds
Iron